Early-Phase Drug Development in Rare Cancers: A Decade of Progress and Future Directions
8 affiliations
- 1One Brooklyn Health—Interfaith Medical Center Campus, Brooklyn, NY 11213, USA
- 2Comprehensive Cancer Centers of Nevada, Las Vegas, NV 11213, USA
- 3Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas (UNLV), Las Vegas, NV 11213, USA
- 4Department of Medicine, University Nevada, Henderson, NV 11213, USA
- 5Independent Researcher, Nashville, TN 37235, USA
- 6Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
- 7Division of Hematology & Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37235, USA
- 8Vanderbilt-Ingram Cancer Center, Nashville, TN 37235, USA
Abstract
Rare cancers represent a substantial health burden, comprising 25% of cancer mortality. Early-phase oncology trials are essential for rare cancers, where limited patient numbers, biological heterogeneity, and the absence of established standards of care necessitate innovative approaches to drug development. Advances in trial design—including basket, umbrella, and adaptive platforms—have enabled efficient evaluation of molecularly defined subgroups and accelerated identification of clinically meaningful activity across rare tumor types. Early-phase studies have demonstrated the therapeutic potential of antibody-drug conjugates, immunotherapy, targeted agents, and cellular therapies, particularly when guided by predictive biomarkers and tumor-agnostic strategies. These approaches have expanded treatment options for patients with historically limited therapeutic opportunities. Persistent challenges remain, including restricted trial access, difficulties with patient accrual, variability in biomarker assessment, and uncertainty regarding generalizability of outcomes. Additional challenges persist after early-phase trial completion, as continued access to therapies demonstrating clinical benefit may remain limited when regulatory approval or broader clinical availability has not yet been established. Evolving regulatory and collaborative frameworks have partially mitigated these barriers by supporting multi-institutional enrollment and pathway-flexible approvals. Over the past decade, biomarker-driven strategies have been increasingly incorporated into modern clinical trial design, shifting the field away from traditional histology-based approaches. Continued innovation in trial design, biomarker integration, and collaborative infrastructure will be essential to sustaining progress and expanding durable clinical benefit for patients with rare cancers.
Related
- On matrix-analytic Markov modulated models for evolution: application potential and future directions required to advance the field.
- Changes in road traffic fatalities in France over a decade: Disentangling exposure and fatality risk
- SLOPE DETERMINATION ON CONVEX DOMAINS: DIRICHLET DATA AND CRANDALL-PAZY DIRECTIONS
- Work in progress: A Lean-verified conditional reduction of periodic Navier-Stokes regularity on T^3 to a single integrability hypothesis
- On cylindrical directions of regular surfaces in ℝ4 derived from contact with spherical cylinders
BibTeX
@article{myat2026earlyphase,
title = {{Early-Phase Drug Development in Rare Cancers: A Decade of Progress and Future Directions}},
author = {Yin Mon Myat and Kyaw Zin Thein and Lujain Mahmood and Wen Wee Ma and Cathy Eng and Mohamed Shanshal},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18203290},
url = {https://www.mdpi.com/2072-6694/18/20/3290},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Early-Phase Drug Development in Rare Cancers: A Decade of Progress and Future Directions
AU - Yin Mon Myat
AU - Kyaw Zin Thein
AU - Lujain Mahmood
AU - Wen Wee Ma
AU - Cathy Eng
AU - Mohamed Shanshal
PY - 2026
DA - 2026/10/01
JO - Cancers
DO - 10.3390/cancers18203290
UR - https://www.mdpi.com/2072-6694/18/20/3290
AB - Rare cancers represent a substantial health burden, comprising 25% of cancer mortality. Early-phase oncology trials are essential for rare cancers, where limited patient numbers, biological heterogeneity, and the absence of established standards of care necessitate innovative approaches to drug development. Advances in trial design—including basket, umbrella, and adaptive platforms—have enabled efficient evaluation of molecularly defined subgroups and accelerated identification of clinically meaningful activity across rare tumor types. Early-phase studies have demonstrated the therapeutic potential of antibody-drug conjugates, immunotherapy, targeted agents, and cellular therapies, particularly when guided by predictive biomarkers and tumor-agnostic strategies. These approaches have expanded treatment options for patients with historically limited therapeutic opportunities. Persistent challenges remain, including restricted trial access, difficulties with patient accrual, variability in biomarker assessment, and uncertainty regarding generalizability of outcomes. Additional challenges persist after early-phase trial completion, as continued access to therapies demonstrating clinical benefit may remain limited when regulatory approval or broader clinical availability has not yet been established. Evolving regulatory and collaborative frameworks have partially mitigated these barriers by supporting multi-institutional enrollment and pathway-flexible approvals. Over the past decade, biomarker-driven strategies have been increasingly incorporated into modern clinical trial design, shifting the field away from traditional histology-based approaches. Continued innovation in trial design, biomarker integration, and collaborative infrastructure will be essential to sustaining progress and expanding durable clinical benefit for patients with rare cancers.
SN - 2072-6694
ER -